View as an RSS Feed
View Derek Lowe's Articles BY TICKER:
ABBV, ABT, ACOR, AFFY, ALNY, AMGN, ARIA, ARNA, ASTX, AVEO, AZN, BIIB, BIND, BMS, BTIM, CBST, CEPH, CNCE, CPRX, DNDN, ELN, ESALY, EXEL, GALE, GE, GNBT, GNVC, GS, GSK, ITMN, JNJ, KVPBQ, LLY, MDVN, MEDX, MNKD, MRK, MTXX, MYGN, NTMD, NVO, NVS, NWBO, OSIR, OSUKF, PFE, PTCT, RBXLF, RBXZF, RDEA, REGN, RHHBY, RNN, RUK, SEPR, SGP, SHPG, SNSS, SNY, SQNM, SVNTQ, TKPHF, TRGT, VNDA, VSTM, WYE
- Roche Has Problems but RNA Interference Has More
- GSK's Whistle-Blowing Record Is a Good Thing
- How Bad Is the Non-Approval of Arena's Weight Loss Drug?
- Merck vs. J&J: Wait for It
- Sanofi Goes Hostile on Genzyme
- Avandia Goes Down: A Researcher's Rant
- Arena's Weight Loss Drug in Trouble
- Sanofi Still Bidding for Genzyme - And at the Same Price
- Sanofi-Aventis and Genzyme: Walking Away?
- Lilly's Enzyme Inhibitor for Alzheimer's: Worse Than Nothing
- FDA Rightfully Rethinks Approval for Genentech / Roche Breast Cancer Drug
- MannKind / Seaside 88: Not Good News for Investors
- Where Does the WuXi Deal Breakup Leave Charles River?
- The Other Side of Genzyme Takeover Speculation
- Genzyme Giving Sanofi-Aventis the Cold Shoulder?
- Momenta Pharma Closes In on Sanofi Aventis With Biogeneric Approval
- Vivus's Obesity Drug Raises Familiar Questions
- Did SmithKline Bury Avandia Evidence?
- Glaxo's Biotechy World
- Exelixis Gets a Compound Back
- Wyeth's Mylotarg Illustrates the FDA's Thin Line
The Economic Impact of the Genomic Revolution's Failure
Jun. 20, 2010 • Comment!
- A Look at Big Pharma Business Ratios
- Eisai's Oncology Drug Finally Gets Reviewed
- Former Sequenom Executive Charged With Faking It
- Pfizer Halts Heart Failure Drug Trial Early on Good News
- Pfizer's 'Golden Age of Drug Discovery' Announcer Moves on to AstraZeneca
- Astellas Buyout of OSI Pharmaceuticals Gets More Likely
- Biosimilars Aren't So Darn Easy
- China's Outsourcing Future: Rising Costs Are Not Necessarily a Bad Thing
- Intermune Drops Right Back Down Again
- Steve Nissen vs. GlaxoSmithKline: Tie Game, But GSK Looks Very Bad